Asset 1

Colony Forming Cell (CFC) Assay Services

Predict neutropenia, severe anemia, or thrombocytopenia at the preclinical drug development stage.

Discovery’s scientists take a collaborative approach, designing studies tailored to ensure meaningful, predictive data on the hematotoxicity potential of your specific drug candidates.

We have decades of experience performing these assays, so you can trust our cell culture proficiency and lineage-specific colony scoring accuracy. CFC assay data can support your IND submission and these assays are often required by regulatory agencies. CFC assays are highly effective in predicting toxicity at the bone marrow hematopoietic progenitor cell level and can be utilized to evaluate drug efficacy against blood cancer progenitor cells.

Discovery's CFC Assay Service Advantages​

Experts in Cell-Based Assays, Predictive Hematotoxicity,
and Drug Screening Services.

Discovery’s expert cell biologists have developed numerous novel assays, enabling us to offer a broader and more strategic array of services to our clients. Our ongoing innovations accelerate drug discovery and development, ultimately enhancing patient outcomes.

Featured Scientist - Dr. Emer Clarke, VP, Cell Biology

Dr. Clarke has over 25 years of experience in stem cell biology, spanning both clinical and industrial settings. She plays a pivotal role in driving innovations and managing Discovery’s scientific operations, including research and development and client services. Dr. Clarke is also actively involved in client affairs, offering one-on-one consultations, study design, and data analysis.

Featured Resources

Hematopietic Colony Forming Cell (CFC) Assay

The preclinical screening method that helps clients eliminate bad players earlier in the drug development process. White Paper

Colony Forming Cell Assays Predict Compound Induced Toxicities

Colony Forming Cell assays can predict compound induced toxicities including neutropenia, thrombocytopenia, anemia and lymphotoxicity. Video

DB-ALM Protocol n° 101

The haematotoxic potential of xenobiotics is determined by the evaluation of the inhibition of CFU-GM growth. White Paper

Contact Us Today

Quick Links


Development and Clinical
Trial Solutions